Safety and Efficacy of PG101 for Dry Eye Syndrome

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Dry Eye Syndrome

In brief

To evaluate the safety and efficacy of 0.25% PG101 and 1.0% PG101 topical gel suspension compared to placebo when administered two times daily for 14 days in subjects diagnosed with dry eye syndrome

Key facts

Study ID
NCT02078661
Run by
Rhodes Pharmaceuticals, L.P.
People needed
72
Starts
2013-12-01
Expected to finish
2014-01-01
Last updated by the study team
2014-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.